Medical societies to launch large-scale study on vein filter use

Monday, February 4, 2013 11:56 AM

The Society of Interventional Radiology (SIR) and Society for Vascular Surgery (SVS) jointly will launch PRESERVE—the first large-scale, multi-specialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

The study, along with the formation of the IVC Filter Study Group Foundation, are direct actions taken to address the August 2010 FDA medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients.

SIR and SVS are in the process of determining a framework for the PRESERVE (PREdicting the Safety and Effectiveness of InferioR VEna Cava Filters) study, with the goal of obtaining a functional view of all filters placed in the U.S.

"PRESERVE data will allow a systematic, functional view, representative of all filters placed in the U.S., thus, all stakeholders—individuals, health care professionals, insurers and government regulators—will be armed with the knowledge they need on patient risk and, subsequently, quality improvement in filter placement, management and retrieval," said Marshall E. Hicks, M.D., FSIR, president of SIR.

Peter Gloviczki, M.D., president of SVS, added, “This is a paradigm-shifting initiative: interventional radiologists and vascular surgeons collaborating to launch a large-scale prospective study evaluating inferior vena cava filters reveals a lot about each specialty's focus--and that focus is on patients, first and foremost.”

The five-year study will evaluate the overall safety and efficacy of filters placed by doctors and intends to enroll 1,800 patients at approximately 50 centers in the U.S. Members of the IVC Filter Study Group Foundation collectively discussed ways to respond to the FDA's stated concerns. SIR and SVS are in the process of making a final decision for a CRO, completing protocol development and submitting the study for investigational device exemption study with HIPAA compliance.

Study directors are Matthew S. Johnson, M.D., FSIR, Indiana University School of Medicine, and David L. Gillespie M.D., FACS, University of Rochester School of Medicine and Dentistry. Most filter manufacturers have agreed to participate in the study.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs